- Larimar Therapeutics Inc To Provide a Program Update TranscriptFeb 12, 2024
- Larimar Therapeutics Inc at Guggenheim Securities Inflammation & Immunology Conference TranscriptNov 07, 2023
- Larimar Therapeutics Inc To Discuss Phase 2 dose exploration trial of CTI-1601 TranscriptJul 25, 2023
- Larimar Therapeutics Inc CTI-1601 May 2023 Program Update Conference Call TranscriptMay 15, 2023
- Larimar Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) TranscriptApr 04, 2023
- 9Larimar Therapeutics Inc at Guggenheim Healthcare Talks: Immunology and Neurology Day TranscriptNov 15, 2022
- Larimar Therapeutics Inc To Discuss Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 TranscriptSep 14, 2022
- Larimar Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) TranscriptJul 15, 2021
- Q1 2021 Larimar Therapeutics Inc Earnings Call TranscriptMay 11, 2021$8.36 (-36.28%)Earnings
- Zafgen Inc and Chondrial Therapeutics Announce Definitive Merger Agreement - M&A Call TranscriptDec 18, 2019
- Q4 2018 Zafgen Inc Earnings Call TranscriptMar 11, 2019Earnings
Larimar Therapeutics Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript
Okay. What time is it? Good afternoon, everyone. My name is Yatin Suneja. I am one of the biotech analysts here at Guggenheim. Welcome to our 5th Annual I&I Conference.
It's day two, and it is my pleasure to welcome our next presenting company, Larimar. We have two executives from the company here. We have President and Chief Executive Officer, Carole Ben-Maimon; and we also have in the audience Mike Celano, the Chief Financial Officer.
Carole, why don't I hand it over to you? Why don't you just walk us through the Larimar story? Talk to us the origins of the company, what are the few key milestones that are coming up in the next, let's say, 12 months or so. And I do have a set of questions, and then we'll go dive a little more deeper into the program.
So it's all yours, Carole. Thank you.
Thank you, and thanks for having us. Really appreciate it. And thanks for everybody for coming.
So
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)